PMID- 37383395
OWN - NLM
STAT- MEDLINE
DCOM- 20230705
LR  - 20230705
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 14
DP  - 2023
TI  - Utilization of glucagon-like peptide-1 receptor agonists in children and 
      adolescents in China: a real-world study.
PG  - 1170127
LID - 10.3389/fendo.2023.1170127 [doi]
LID - 1170127
AB  - BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been widely 
      used in treating type 2 diabetes mellitus (T2DM) and obesity in adults, but 
      scientific research about the indication in children and adolescents is scarce. 
      The current study aims to explore the prescriptions of GLP-1RAs in children and 
      adolescents in China and to evaluate its rationality. METHODS: GLP-1RA 
      prescriptions of children and adolescents were retrospectively obtained from the 
      Hospital Prescription Analysis Cooperative Project. The study extracted 
      information on patient's demographic characteristics, monotherapy and combination 
      therapy of GLP-1RAs, and trends in GLP-1RA usage from 2016 to 2021. The 
      rationality of GLP-1RA prescriptions was comprehensively assessed based on the 
      indications approved by China National Medical Products Administration (NMPA), 
      the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), 
      Pharmaceuticals and Medical Devices Agency (PMDA), and published randomized 
      controlled trials (RCTs). RESULTS: A total of 234 prescriptions from 46 hospitals 
      were included, with a median age of 17 years old. The majority of patients were 
      diagnosed with overweight/obesity or prediabetes/diabetes, accounting for 43.59% 
      and 46.15%, respectively. There were 88 patients on GLP-1RA monotherapy. GLP-1RAs 
      plus metformin was the most common combination therapy (38.89%). 12.39% of 
      patients were found a co-administration with orlistat. The share of 
      overweight/obesity prescriptions increased from 27% in 2016 to 54% in 2021, 
      whereas prediabetes/diabetes prescriptions declined from 55% to 42%. The 
      prescriptions were divided into appropriate and questionable groups according to 
      the diagnosis, and the potentially questionable prescription was related to age 
      (p = 0.017), department visited (p = 0.002), and any hospitalization (p < 0.001). 
      CONCLUSIONS: This study described the prescribing of GLP-1RAs in children and 
      adolescents. Our findings indicated that the utilization of GLP-1RAs has 
      increased from 2016 to 2021. There was a strong basis for administering GLP-1RAs 
      in overweight/obesity and prediabetes/diabetes, whereas the evidence was 
      insufficient in other conditions. It is crucial to demand robust and sustained 
      efforts to enhance the awareness of the safety of utilization of GLP-1RAs in 
      children and adolescents.
CI  - Copyright (c) 2023 Yan, Gong, Jiang, Gao, Guo, Huo, Zhao and Li.
FAU - Yan, Yilong
AU  - Yan Y
AD  - Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - Department of Clinical Pharmacology, School of Pharmaceutical Sciences, Capital 
      Medical University, Beijing, China.
FAU - Gong, Ying
AU  - Gong Y
AD  - Department of Pharmacy, Dongfang Hospital, Beijing University of Chinese 
      Medicine, Beijing, China.
FAU - Jiang, Meizhu
AU  - Jiang M
AD  - Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - Department of Clinical Pharmacology, School of Pharmaceutical Sciences, Capital 
      Medical University, Beijing, China.
FAU - Gao, Yiming
AU  - Gao Y
AD  - Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
AD  - Department of Clinical Pharmacology, School of Pharmaceutical Sciences, Capital 
      Medical University, Beijing, China.
FAU - Guo, Shanshan
AU  - Guo S
AD  - Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
FAU - Huo, Jiping
AU  - Huo J
AD  - Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
FAU - Zhao, Zhigang
AU  - Zhao Z
AD  - Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
FAU - Li, Cao
AU  - Li C
AD  - Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230613
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Humans
MH  - China/epidemiology
MH  - Glucagon-Like Peptide-1 Receptor
MH  - Obesity
MH  - Overweight
MH  - *Prediabetic State
MH  - United States
PMC - PMC10293789
OTO - NOTNLM
OT  - GLP-1RA
OT  - adolescents
OT  - children
OT  - diabetes
OT  - obesity
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/06/29 13:42
MHDA- 2023/07/03 06:41
PMCR- 2023/01/01
CRDT- 2023/06/29 11:50
PHST- 2023/02/20 00:00 [received]
PHST- 2023/05/29 00:00 [accepted]
PHST- 2023/07/03 06:41 [medline]
PHST- 2023/06/29 13:42 [pubmed]
PHST- 2023/06/29 11:50 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2023.1170127 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2023 Jun 13;14:1170127. doi: 
      10.3389/fendo.2023.1170127. eCollection 2023.